| Ovidrel (choriogonadotropin alfa) / EMD Serono |
NCT00230815: A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction |
|
|
| Completed | 3b | 62 | US | Follitropin alfa injected by Pen device, Gonal-f®, Recombinant Human Choriogonadotropin (r-hCG), Ovidrel®, Choriogonadotropin alfa | EMD Serono | Infertility | 11/05 | 11/05 | | |
NCT01081756: A Study Using Recombinant Human Chorionic Gonadotrophin (rhCG, Ovidrel®) in the Induction of Final Follicle Maturation and Early Luteinization in Chinese Women Undergoing in Vitro Fertilization and Embryo Transfer (IVF/ET) |
|
|
| Completed | 3 | 218 | RoW | r-hCG, Ovitrelle or Ovidrel, Urinary-hCG, Profasi | Merck KGaA, Darmstadt, Germany | Infertility | | 09/04 | | |
NCT01152866: An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART) |
|
|
| Completed | 3 | 3 | Canada | Choriogonadotropin alpha (r-hCG), Ovidrel | EMD Serono | Ovulation Induction, Infertility | 12/04 | 12/04 | | |
NCT00335569: Clinical Tolerance and Equivalence of hCG-IBSA vs Recombinant Human Chorionic Gonadotrophin in Women Undergoing In Vitro Fertilisation |
|
|
| Completed | 3 | 144 | Europe | hCG-IBSA | IBSA Institut Biochimique SA | Infertility | | 12/08 | | |
NCT00948805: Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment |
|
|
| Unknown status | 3 | 25 | RoW | GnRH agonist, Ovidrel, Zoladex, Gonal, Control | University of Sao Paulo | Infertility | 12/09 | 07/10 | | |
NCT00747617: Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS) |
|
|
| Completed | 3 | 25 | US | recombinant human chorionic gonadotropin, Ovidrel | University of California, San Diego | Polycystic Ovary Syndrome | 04/10 | 09/10 | | |
| Completed | 3 | 136 | Europe | Cetrorelix acetate, Cetrotide®, Recombinant Human Choriogonadotropin (r-hCG), Ovitrelle®, Recombinant human follicle stimulating hormone (r-hFSH) | Merck KGaA, Darmstadt, Germany, Merck Serono S.A.S, France | Polycystic Ovarian Syndrome | 10/11 | 02/12 | | |
| Completed | 3 | 202 | Europe, RoW | Gonal-f®, Follitropin alfa, Pergoveris®, Recombinant human chorionic gonadotropin (r-hCG), Ovidrel®, Ovitrelle® | Merck KGaA, Darmstadt, Germany, Merck Serono S.A., Geneva, Merck A/S, Denmark, Merck OY, Finland, Merck Serono S.A.S, France, Merck Serono GmbH, Germany, Merck A.E., Greece, Merck B.V., Netherlands, Merck SP. Z.O.O., Poland, Merck Serono S.P.A., Italy, Merck Services U.K. Ltd, UK, LLC Merck, Russia, Merck spol. s r.o., Slovakia, Merck Pharma, K.S., Slovakia | Assisted Reproductive Techniques, Reproductive Technology, Assisted | 10/12 | 10/12 | | |
| Completed | 3 | 180 | RoW | r-hCG | Dong-A Pharmaceutical Co., Ltd. | Hyperovulation Induction for Assisted Reproduction Treatment | 02/13 | | | |
NCT01154192: Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) |
|
|
| Completed | 3 | 24 | US | Dexamethasone, recombinant human chorionic gonadotropin (r-hCG), Ovidrel | University of California, San Diego, University of Virginia | PCOS | 07/14 | 09/14 | | |
| Completed | 3 | 939 | Europe | Pergoveris®, r-hFSH/r-hLH, Follitropin alfa/Lutropin alfa, GONAL-f®, r-hFSH, Follitropin alfa, Recombinant human chorionic gonadotrophin (r-hCG), Ovidrel®, Ovitrelle®, choriogonadotropin alfa | Merck KGaA, Darmstadt, Germany | Infertility | 08/15 | 08/15 | | |
2009-017674-20: Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoingassisted reproductive technologies.A multi-national, multi-centre, randomised, controlled, assessor-blind, parallel groupPhase III study including follow-up periods |
|
|
| Completed | 3 | 80 | Europe | XM17, Gonal-f, Metrelef, Ovitrelle, XM17, Gonal-f®, Metrelef, Ovitrelle, Gonal-f®, Metrelef, Ovitrelle | BioGeneriX AG | infertile but ovulatory women undergoing superovulation forassisted reproduction technologies | | 09/11 | | |
| Completed | 3 | 234 | Europe | Ganirelix 0.25 mg., ORGALUTRAN®., Recombinant choriogonadotropin alfa, OVITRELLE®., Micronized natural progesterone., PROGEFFIK®. | Instituto de Investigacion Sanitaria La Fe | Infertility | 06/17 | 06/17 | | |
FASHION, NCT02449889: A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation |
|
|
| Completed | 3 | 176 | RoW | highly purified human chorionic gonadotropin, CHORAPUR, BREVACTID, recombinant human chorionic gonadotropin, OVIDREL, OVITRELLE | Ferring Pharmaceuticals | Infertility | 07/17 | 03/18 | | |
| Completed | 3 | 160 | RoW | Recombinant Human Chorionic Gonadotrophin, Ovitrelle, human chorionic gonadotrophin + gonadotrophin releasing hormone agonist | Assiut University | Increase Pregnancy Rate | 10/18 | 02/19 | | |
NCT02862782: Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles |
|
|
| Unknown status | 3 | 1000 | NA | hCG (Ovitrelle 250 mcg mcg - Merck Serono), hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh) | Tel-Aviv Sourasky Medical Center | In-vitro Fertilization | 09/19 | 09/19 | | |
NCT03440359: Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole |
|
|
| Completed | 2/3 | 52 | US | Progesterone Vaginal Gel 8%, Crinone 8% vaginal gel, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, recombinant hCG 250 mcg, Intrauterine insemination or timed intercourse | Eastern Virginia Medical School, Watson Pharmaceuticals | Polycystic Ovary Syndrome | 11/16 | 12/17 | | |
